XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07688577 by Xilio Development, Inc., with a registry enrolment figure of 140 participants, started 2026-08 and due to reach its primary completion in 2029-11. Interventions recorded: XTX501. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor. Primary outcome: Incidence of Dose Limiting Toxicities (DLTs) in Part 1A; Incidence of treatment-emergent adverse events (Phase 1 and Phase 2); Incidence of serious adverse events (Phase 1 and Phase 2). Lung eligibility wording from the registry: "* Metastatic NSCLC:". No results are recorded here; the registry entry is the source.